TherapeuticsMD (TXMD) Operating Leases (2019 - 2026)

TherapeuticsMD's Operating Leases history runs 8 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• Quarterly Operating Leases fell 19.06% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 19.06% YoY) and the FY2025 annual result came in at $5.1 million, down 7.58% from the prior year.
• Operating Leases was $4.8 million for Q1 2026 at TherapeuticsMD, down from $5.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $8.0 million in Q4 2023 and bottomed at $4.8 million in Q1 2026.
• A 5-year average of $6.5 million and a median of $6.7 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases gained 8.63% — and 2024, when it slumped 30.77%.
• TherapeuticsMD's Operating Leases stood at $7.4 million in 2022, then climbed by 8.63% to $8.0 million in 2023, then plunged by 30.77% to $5.5 million in 2024, then declined by 7.58% to $5.1 million in 2025, then retreated by 5.82% to $4.8 million in 2026.
• Business Quant data shows TXMD's Operating Leases at $4.8 million in Q1 2026, $5.1 million in Q4 2025, and $5.4 million in Q3 2025.